Daily Summary
An Australian forensic study reconstructed the face of Santa Teresa de Jesús using her mummified remains, offering new details about her appearance and health. Meanwhile, the US FDA approved a novel antibiotic for UTIs in women and girls and expanded the use of a heart drug for a rare condition, marking significant progress in innovative treatments. In public health developments, Swiss doctors are prescribing free museum visits as art therapy to improve well-being, while UK drugmakers warn that a higher medicine sales tax is making the country less attractive for investment.
US FDA Expands Approval for Alnylam's Amvuttra to Treat Rare Heart Disease
On March 20, 2025, the U.S. FDA approved Alnylam's Amvuttra for ATTR-CM, extending its use from nerve damage to also target dangerous heart complications associated with the disease.
Así era el rostro de Santa Teresa de Jesús según el Victorian Institute of Forensic Medicine de Australia
El Victorian Institute of Forensic Medicine de Australia reconstruyó el rostro de Santa Teresa de Jesús a partir de datos antropométricos e imágenes radiográficas, mostrando a la santa a los 50 años. La presentación coincidió con el aniversario de su nacimiento en marzo de 1515 y destacó rasgos físicos y condiciones de salud relevantes.
Stressed? Sick? Swiss Town Lets Doctors Prescribe Free Museum Visits as Art Therapy
A new two-year pilot in Neuchâtel, Switzerland allows doctors to prescribe free museum visits as art therapy to boost mental and physical well-being.
UK Medicine Sales Tax Hike Deemed 'Uninvestable', Warns Pharma
Drugmakers warn that the higher UK medicine sales tax is rendering the market 'uninvestable', leading to delays in new product launches and reduced NHS partnerships.
US FDA greenlights GSK’s Blujepa for UTIs in women and girls
The FDA approved GSK’s new antibiotic Blujepa for treating uncomplicated UTIs in females aged 12 and older after successful phase III trials demonstrated its efficacy compared to nitrofurantoin.